This is a preview of subscription content, log in via an institution to check access.
Notes
fms-like tyrosine kinase 3
The study was sponsored by Novartis.
Reference
Tremblay G, et al. Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom. Cost Effectiveness and Resource Allocation : 4 Oct 2018. Available from: URL: https://doi.org/10.1186/s12962-018-0153-4
Rights and permissions
About this article
Cite this article
Midostaurin cost-effective option in acute myeloid leukaemia. PharmacoEcon Outcomes News 814, 16 (2018). https://doi.org/10.1007/s40274-018-5359-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5359-3